TY - JOUR
T1 - Wnt/wingless pathway activation is promoted by a critical threshold of axin maintained by the tumor suppressor APC and the ADP-ribose polymerase tankyrase
AU - Wang, Zhenghan
AU - Tacchelly-Benites, Ofelia
AU - Yang, Eungi
AU - Thorne, Curtis A.
AU - Nojima, Hisashi
AU - Lee, Ethan
AU - Ahmed, Yashi
N1 - Funding Information:
We thank the investigators listed in Materials and Methods for generously sharing reagents and V. Marlar for technical assistance. We thank Claudio Pikielny, Ai Tian, and Hassina Benchabane for critical reading and thoughtful comments on this manuscript. This work was funded by grants from the National Institutes of Health (RO1CA105038 to Y.A., R01GM081635 and R01GM103926 to E.L., and P40OD018537 to the Bloomington Drosophila Stock Center), the Emerald Foundation (to Y.A.), the Norris Cotton Cancer Center (to Y.A.), and the National Science Foundation (DBI-1039423 for the purchase of a Nikon A1RSi confocal microscope).
Publisher Copyright:
© 2016 by the Genetics Society of America.
PY - 2016/5
Y1 - 2016/5
N2 - Wnt/β-catenin signal transduction directs metazoan development and is deregulated in numerous human congenital disorders and cancers. In the absence of Wnt stimulation, a multiprotein “destruction complex,” assembled by the scaffold protein Axin, targets the key transcriptional activator b-catenin for proteolysis. Axin is maintained at very low levels that limit destruction complex activity, a property that is currently being exploited in the development of novel therapeutics for Wnt-driven cancers. Here, we use an in vivo approach in Drosophila to determine how tightly basal Axin levels must be controlled for Wnt/Wingless pathway activation, and how Axin stability is regulated. We find that for nearly all Wingless-driven developmental processes, a three- to fourfold increase in Axin is insufficient to inhibit signaling, setting a lower-limit for the threshold level of Axin in the majority of in vivo contexts. Further, we find that both the tumor suppressor adenomatous polyposis coli (APC) and the ADP-ribose polymerase Tankyrase (Tnks) have evolutionarily conserved roles in maintaining basal Axin levels below this in vivo threshold, and we define separable domains in Axin that are important for APC- or Tnks-dependent destabilization. Together, these findings reveal that both APC and Tnks maintain basal Axin levels below a critical in vivo threshold to promote robust pathway activation following Wnt stimulation.
AB - Wnt/β-catenin signal transduction directs metazoan development and is deregulated in numerous human congenital disorders and cancers. In the absence of Wnt stimulation, a multiprotein “destruction complex,” assembled by the scaffold protein Axin, targets the key transcriptional activator b-catenin for proteolysis. Axin is maintained at very low levels that limit destruction complex activity, a property that is currently being exploited in the development of novel therapeutics for Wnt-driven cancers. Here, we use an in vivo approach in Drosophila to determine how tightly basal Axin levels must be controlled for Wnt/Wingless pathway activation, and how Axin stability is regulated. We find that for nearly all Wingless-driven developmental processes, a three- to fourfold increase in Axin is insufficient to inhibit signaling, setting a lower-limit for the threshold level of Axin in the majority of in vivo contexts. Further, we find that both the tumor suppressor adenomatous polyposis coli (APC) and the ADP-ribose polymerase Tankyrase (Tnks) have evolutionarily conserved roles in maintaining basal Axin levels below this in vivo threshold, and we define separable domains in Axin that are important for APC- or Tnks-dependent destabilization. Together, these findings reveal that both APC and Tnks maintain basal Axin levels below a critical in vivo threshold to promote robust pathway activation following Wnt stimulation.
KW - APC
KW - Axin
KW - Tankyrase
KW - Wingless
UR - http://www.scopus.com/inward/record.url?scp=84979892842&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84979892842&partnerID=8YFLogxK
U2 - 10.1534/genetics.115.183244
DO - 10.1534/genetics.115.183244
M3 - Article
C2 - 26975665
AN - SCOPUS:84979892842
VL - 203
SP - 269
EP - 281
JO - Genetics
JF - Genetics
SN - 0016-6731
IS - 1
ER -